Correlation Between Intellia Therapeutics and Vertex Pharmaceuticals

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Intellia Therapeutics and Vertex Pharmaceuticals at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Intellia Therapeutics and Vertex Pharmaceuticals into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Intellia Therapeutics and Vertex Pharmaceuticals, you can compare the effects of market volatilities on Intellia Therapeutics and Vertex Pharmaceuticals and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Intellia Therapeutics with a short position of Vertex Pharmaceuticals. Check out your portfolio center. Please also check ongoing floating volatility patterns of Intellia Therapeutics and Vertex Pharmaceuticals.

Diversification Opportunities for Intellia Therapeutics and Vertex Pharmaceuticals

0.18
  Correlation Coefficient

Average diversification

The 3 months correlation between Intellia and Vertex is 0.18. Overlapping area represents the amount of risk that can be diversified away by holding Intellia Therapeutics and Vertex Pharmaceuticals in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Vertex Pharmaceuticals and Intellia Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Intellia Therapeutics are associated (or correlated) with Vertex Pharmaceuticals. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Vertex Pharmaceuticals has no effect on the direction of Intellia Therapeutics i.e., Intellia Therapeutics and Vertex Pharmaceuticals go up and down completely randomly.

Pair Corralation between Intellia Therapeutics and Vertex Pharmaceuticals

Given the investment horizon of 90 days Intellia Therapeutics is expected to under-perform the Vertex Pharmaceuticals. In addition to that, Intellia Therapeutics is 2.18 times more volatile than Vertex Pharmaceuticals. It trades about -0.11 of its total potential returns per unit of risk. Vertex Pharmaceuticals is currently generating about 0.03 per unit of volatility. If you would invest  46,813  in Vertex Pharmaceuticals on November 29, 2024 and sell it today you would earn a total of  1,097  from holding Vertex Pharmaceuticals or generate 2.34% return on investment over 90 days.
Time Period3 Months [change]
DirectionMoves Together 
StrengthInsignificant
Accuracy100.0%
ValuesDaily Returns

Intellia Therapeutics  vs.  Vertex Pharmaceuticals

 Performance 
       Timeline  
Intellia Therapeutics 

Risk-Adjusted Performance

Very Weak

 
Weak
 
Strong
Over the last 90 days Intellia Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. Despite uncertain performance in the last few months, the Stock's essential indicators remain somewhat strong which may send shares a bit higher in March 2025. The current disturbance may also be a sign of long term up-swing for the company investors.
Vertex Pharmaceuticals 

Risk-Adjusted Performance

Weak

 
Weak
 
Strong
Compared to the overall equity markets, risk-adjusted returns on investments in Vertex Pharmaceuticals are ranked lower than 2 (%) of all global equities and portfolios over the last 90 days. In spite of fairly strong basic indicators, Vertex Pharmaceuticals is not utilizing all of its potentials. The recent stock price disturbance, may contribute to short-term losses for the investors.

Intellia Therapeutics and Vertex Pharmaceuticals Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Intellia Therapeutics and Vertex Pharmaceuticals

The main advantage of trading using opposite Intellia Therapeutics and Vertex Pharmaceuticals positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Intellia Therapeutics position performs unexpectedly, Vertex Pharmaceuticals can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Vertex Pharmaceuticals will offset losses from the drop in Vertex Pharmaceuticals' long position.
The idea behind Intellia Therapeutics and Vertex Pharmaceuticals pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Suggestion module to get suggestions outside of your existing asset allocation including your own model portfolios.

Other Complementary Tools

Options Analysis
Analyze and evaluate options and option chains as a potential hedge for your portfolios
Portfolio Volatility
Check portfolio volatility and analyze historical return density to properly model market risk
Portfolio Center
All portfolio management and optimization tools to improve performance of your portfolios
Stocks Directory
Find actively traded stocks across global markets
Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance